Announcement PDF RNS Number : 2123A OptiBiotix Health PLC 01 February 2022 OptiBiotix Health plc ("OptiBiotix" or the "Company") Consumer study of LPLDL® in Cholbiome® products OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has carried out a consumer study (n=46) on its CholBiome® products. CholBiome®X3 and CholBiome®BP are ProBiotix's patented and proprietary formulations developed to reduce cardiovascular disease risk using the probiotic strain LPLDL®, on which a third double-blind, randomised, placebo-controlled human clinical study was recently published documenting a statistical significant effect of LPLDL® in reducing total cholesterol, LDL-cholesterol and APO-B : Third human clinical trial LPLDL® in hypercholesterolemic adults - ScienceDirect. (RNS: 18 January 2022) Human studies are essential in providing a scientific, clinical, and statistical evidence base for use of an intervention in a controlled environment. However, it's important to check these findings reflect the real-world use of products which is best assessed by receiving structured feedback from consumers of a product. The consumer study was carried out by contacting customers who purchased CholBiome® products from the website https://optibiotix.online. The results of the survey are shown below:I. 96% of consumers who had taken CholBiome®X3 and who had measured their total cholesterol levels reported that their levels had reduced. Of these:a. 17% reported reductions in total cholesterol of >30% b. 50% reported reductions in total cholesterol of between 16-30% c. 29% reported reductions in total cholesterol of between 1-15% II. 88% of consumers stated that their LDL-cholesterol (bad cholesterol) had been reduced (with 8% not knowing their LDL cholesterol levels). III. This level of reduction was sustained with 93% of users who took the product for more than 1 year reporting reduced levels of total and LDL cholesterol. IV. No consumers taking CholBiome®X3 reported any side effects or tolerance issues. These results build upon a consumer study carried out in Dec 2019 (n=20) on CholBiome®X3 in which 95% of users stating that the product was effective, and 90% reporting they would recommend the product to family and friends. Mikkel Hvid-Hansen, Commercial Director of Probiotics, commented: "The combination of scientific, clinical, and consumer studies on LPLDL®, and formulations like the CholBiome® product range provide a growing body of evidence for its safe and effective use in reducing biomarkers of cardiovascular risk like total cholesterol, LDL cholesterol, and Apolipoprotein B. We now have five scientific publications, three human studies, two consumer studies and numerous positive product reviews which gives us confidence in the use of LPLDL®. We now feel we have evidence broadly comparable to Phase I/II pharmaceutical studies which we can use to open up further partnering or licensing opportunities for use of LPLDL® as an OTC product by itself or in combination with existing treatments (e.g. statins), or as a drug biotherapeutic in markets outside the USA." For further information, please contact: OptiBiotix Health plc Stephen O'Hara, Chief Executive Cenkos Securities plc (Broker) Callum Davidson / Neil McDonald Michael Johnson / Russell Kerr (Sales) Walbrook PR Ltd Anna Dunphy www.optibiotix.com Contact via Walbrook below Tel: 020 7397 8900 Mob: 07876 741 001 This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRABKDBPABKDCDN